TwinBeech Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

TwinBeech Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Buy	+34,300	New	+$1.01M	0.2%	150
2023 Q4	–	Sell	-213,460	Closed	-$2.5M	–	683
2023 Q3	$2.5M	Buy	213,460 +189,810	+803%	+$2.54M	0.05%	378
2023 Q2	$318K	Sell	23,650 -98,599	-81%	-$1.42M	0.01%	540
2023 Q1	$2.03M	Buy	+122,249	New	+$2.02M	0.04%	376

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TwinBeech Capital's CPRX Position: Q2 2026 in Review

TwinBeech Capital opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 34,300 shares worth $1.08M. The stake represents 0.2% of the portfolio and ranks #150 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in CPRX as recently as Q3 2023.

TwinBeech Capital first reported a position in CPRX in Q1 2023 and has held it in 4 quarters since. The position peaked at $2.5M in Q3 2023. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

TwinBeech Capital held 34,300 shares of Catalyst Pharmaceutical worth $1.08M as of Q2 2026.
Catalyst Pharmaceutical was a new TwinBeech Capital position in Q2 2026.
Catalyst Pharmaceutical made up 0.2% of TwinBeech Capital's portfolio in Q2 2026, its #150 holding.
TwinBeech Capital first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 4 quarters since.
TwinBeech Capital's Catalyst Pharmaceutical position peaked at $2.5M in Q3 2023.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.